Operator: We’ll take our next question from Robbie Marcus with JPMorgan. Please go ahead.
Tom Polen: Good morning, Robbie.
Robbie Marcus: Good morning and congrats on nice quarter. Chris, maybe to dig into some of the points you made already. COVID testing is a high-margin business going down. How much of the base business upside in guidance is coming from the combo COVID test? And then a lot of competitors are outperforming on COVID testing and potentially raising numbers for the year. I guess, how are you thinking about just Becton, Dickinson in the framework of COVID testing and your assumptions underlying how testing will be used for the balance of the year? Thanks.
Tom Polen: Yes. Good question, Robbie. So I’ll start with the COVID and Dave can add in here. But I would say a few things. One is, so our COVID testing as you know is primarily in professional settings. And when we talk about our €“ and molecular, to a degree as well, too, we don’t have a strong presence in At Home. We do have an At Home test, but it’s not it’s a €“ it’s not nearly as big of a presence as in our professional setting. So I think perhaps where you see the most outsized performance there is in company €“ is from companies with a large At Home presence where you’ve just seen a lot of the COVID testing migrate to At Home versus in professional settings since it’s so easy to do and people can do that without going into a clinician.
So I think that’s one factor probably influencing some of the delta for us. As you know, we do have a combo test in development for At Home, and we’ll share once we get that, hopefully that EUA and able to launch that. Dave, any other comments to add there on COVID?
Dave Hickey: Yes. Hey Robbie. I mean I think, Tom, you captured well. I think when we did our At Home COVID test; we made a very deliberate decision to pursue a digital strategy. You saw the acquisition that we made of Scanwell. We were very much aligned to the test, treat and trace reporting dynamics. And we intentionally sort of targeted that digital ecosystem with a higher price, higher margin rather than the visually red at-home test. We still think on a go-forward basis, as the sort of, let’s say, the sort of the government contracts and things abate, as testing perhaps becomes more regulated At Home, 510(k) environments and so on, a digital ecosystem, again plays into the smart connected care of BD will be important. But I think for us, we just look at it all as we’re seeing the softening in the COVID decline.
We firmly believe that the standard of care going forward will be these €“ in an endemic type of approach, these combination tests and we’ve built a portfolio across BD MAX, BD COR, Veritor and potentially Veritor At-Home across all of these combination portfolios.
Tom Polen: I think the good thing, Robbie that we would look at as is that we’re really getting more to a durable revenue number in that, right? So I think as we look at 2023, it’s a number that could be very much in line with how we think about it playing out in future years as well at that level where there’s not still significantly high numbers that would drop in the future that were really at a kind of a durable level of performance in those categories. Chris, any other?
